NCT04732286

A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy

A Phase IIIb, Single Arm, Multicenter Study of Atezolizumab in Combination With Bevacizumab to Investigate Safety and Efficacy in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 100 (actual)
• Sponsor: Hoffmann-La Roche · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase IIIb, one arm, multicenter, open-label study primarily designed to evaluate the safety of atezolizumab + bevacizumab in participants with unresectable or unsuitable for locoregional treatments for metastatic HCC not previously treated with systemic therapy. As part of its secondary objectives, this study is also designed to evaluate the efficacy of atezolizumab and bevacizumab in these participants.

Conditions

• Carcinoma, Hepatocellular

Interventions

Type	Name	Description
DRUG	Atezolizumab	Atezolizumab will be administered intravenously at a dose of 1200 mg on Day 1 of each 21-day cycle.
DRUG	Bevacizumab	Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.

Timeline

• Start date: 2021-05-04
• Primary completion: 2024-04-26
• Completion: 2024-04-26
• First posted: 2021-02-01
• Last updated: 2025-05-08
• Results posted: 2025-05-08

Locations

25 sites across 1 country: Spain